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Aims: To evaluate safety, efficacy and glucose turnover during closed-loop with meal announcement using reduced prandial insulin boluses in
adolescents with type 1 diabetes (T1D).
Methods: We conducted a randomized crossover study comparing closed-loop therapy with standard prandial insulin boluses versus closed-loop
therapy with prandial boluses reduced by 25%. Eight adolescents with T1D [3 males; mean (standard deviation) age 15.9 (1.5) years, glycated haemoglobin
74 (17) mmol/mol; median (interquartile range) total daily dose 0.9 (0.7, 1.1) IU/kg/day] were studied on two 36-h-long visits. In random order, subjects
received closed-loop therapy with either standard or reduced insulin boluses administered with main meals (50–80 g carbohydrates) but not with snacks
(15–30 g carbohydrates). Stable-label tracer dilution methodology measured total glucose appearance (Ra_total) and glucose disposal (Rd).
Results: The median (interquartile range) time spent in target (3.9–10mmol/l) was similar between the two interventions [74 (66, 84)% vs 80 (65, 96)%;
p= 0.87] as was time spent above 10mmol/l [21.8 (16.3, 33.5)% vs 18.0 (4.1, 34.2)%; p= 0.87] and below 3.9mmol/l [0 (0, 1.5)% vs 0 (0, 1.8)%; p= 0.88].
Mean plasma glucose was identical during the two interventions [8.4 (0.9) mmol/l; p= 0.98]. Hypoglycaemia occurred once 1.5 h post-meal during
closed-loop therapy with standard bolus. Overall insulin delivery was lower with reduced prandial boluses [61.9 (55.2, 75.0) vs 72.5 (63.6, 80.3) IU; p= 0.01]
and resulted in lower mean plasma insulin concentration [186 (171, 260) vs 252 (198, 336) pmol/l; p= 0.002]. Lower plasma insulin was also documented
overnight [160 (136, 192) vs 191 (133, 252) pmol/l; p= 0.01, pooled nights]. Ra_total was similar [26.3 (21.9, 28.0) vs 25.4 (21.0, 29.2) μmol/kg/min;
p= 0.19] during the two interventions as was Rd [25.8 (21.0, 26.9) vs 25.2 (21.2, 28.8) μmol/kg/min; p= 0.46].
Conclusions: A 25% reduction in prandial boluses during closed-loop therapy maintains similar glucose control in adolescents with T1D whilst lowering
overall plasma insulin levels. It remains unclear whether closed-loop therapy with a 25% reduction in prandial boluses would prevent postprandial
hypoglycaemia.
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Introduction
The treatment goal of type 1 diabetes (T1D) is to maintain tight
glycaemic control whilst minimizing the risk of hypoglycaemia
[1], but this is particularly challenging during adolescence [2].
The Diabetes Control and Complications Trial showed that,
even when intensified insulin treatment was rigorously applied,
glycated haemoglobin (HbA1c) levels were higher in adoles-
cents compared with adults [3]. Data from the T1D Exchange
document that only 20% of young people aged 13–20 years
meet HbA1c targets set by the American Diabetes Association
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and the International Society for Pediatric and Adolescent
Diabetes [4]. The psychological and social aspects associated
with adolescence often lead to worsening of metabolic control
exacerbated by increased insulin requirements related to the
physiological changes of puberty.
Closed-loop therapy is an emerging treatment method for
T1D [5], adopting glucose-responsive insulin delivery directed
by a control algorithm according to real-time sensor glucose
levels. The efficacy and safety of closed-loop therapy in adoles-
cents have been demonstrated in multiple short-term clinical
trials, mainly in laboratory conditions, andmore recently in the
outpatient and home settings by us and others [6–10]. In our
studies, between-meal insulin delivery is automated and mod-
ulated by the algorithm, whereas prandial insulin boluses are
administered manually using a bolus calculator as per standard
clinical practice. Compared with conventional insulin pump
therapy, this so-called closed-loop with meal announcement
improves the time spent in normoglycaemia whilst reducing
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the risk of hypoglycaemia in children and adolescents as well
as in adults and pregnant women with T1D [6,7,11,12]. These
outcomes were also observed in a group of adolescents over
a 36-h period in the clinical research facility [13]; overnight
closed-loop insulin delivery was found to be particularly ben-
eficial, whilst the achievement of optimum glucose levels in
the daytime was complicated by the rapid glucose fluctuations
associated with meals and physical activity. Four out of nine
episodes of hypoglycaemia occurred in the postprandial period
and probably resulted from a high prandial insulin dose.
It is currently unknown if reducing prandial insulin boluses
provides a similar level of control during closed-loop therapy
whilst limiting postprandial hyperinsulinaemia and reducing
risk of post-meal hypoglycaemia. We tested this hypothesis in
the present study and additionally employed a stable-label glu-
cose methodology to measure glucose turnover to determine
the effect of reduced prandial insulin on glucose turnover.
Materials and Methods
Subjects and Study Protocol
The study was conducted at the Wellcome Trust Clinical
Research Facility at Addenbrooke’s Hospital, Cambridge,
UK, and was registered with clinicaltrials.gov (identifier
NCT01629251).
Young people aged 12–18 years with T1D on insulin pump
therapy were recruited through three paediatric diabetes
clinics at Cambridge University Hospital, University College
Hospital London and Norwich Hospital. The inclusion criteria
were T1D (World Health Organization criteria), diabetes
duration of at least 1 year and insulin pump therapy for at
least 3months. Adolescents with poor glycaemic control
[HbA1c >12% (108mmol/mol)], insulin resistance (total daily
dose >2 IU/kg/day) and clinically significant nephropathy or
retinopathy were excluded.
The study adopted an open-label randomized crossover
design. Participants received closed-loop insulin delivery
between meals, combined with manually administered pran-
dial boluses. In random order, standard meal insulin boluses
or reduced meal insulin boluses during two 36-h study visits,
1–6weeks apart, were applied.
Prandial insulin boluses administered with each main
meal were calculated by bolus calculator with insulin-to-
carbohydrate ratios and insulin sensitivity factors being deter-
mined by treating clinicians. On one occasion (closed-loop
therapy with standard meal insulin boluses), the standard
bolus was given at each meal, whereas on the other occasion
(closed-loop therapy with reduced meal insulin boluses), the
bolus at each meal was reduced by 25%.
On each occasion, participants attended the clinical research
facility from 17:30 hours on day 1 until 08:00 hours on day 3.
Continuous glucose monitoring (FreeStyle Navigator®, Abbott
Diabetes Care, Alameda, CA, USA) was established 24–48 h
before each study visit by inserting a single sensor. During the
study visit, the participants’ insulin pump was replaced by a
study pump (Animas® 2020, Animas Corp., West Chester, PA,
USA). The subjects consumed self-selected meals and snacks
from standardized menus that were identical on the two study
visits. They consumed an evening meal (80 g carbohydrates)
at 19:00 hours, breakfast (50 g carbohydrates) at 08:00 hours
and lunch (70 g carbohydrates) at 13:00. Snacks containing 15 g
carbohydrates were given in the evening at 21:00 hours on day 1
and day 2 and in the morning at 10:15 hours on day 2. An after-
noon snack of 30 g carbohydrates was consumed at 16:00 hours
on day 2. No insulin boluses were given with snacks. Subjects
engaged in physical activity on a stationary bicycle for two sep-
arate 20-min sessions at 10:40 and 17:30 hours on day 2.
Closed-loop System
An algorithm based on model-predictive control [6] was used
to adjust basal insulin delivery based on glucose sensor readings
at 15-min intervals from 19:30 hours on day 1 until 08:00 hours
on day 3 for ∼32 h, as previously described [6,13]. A model
predictive algorithm version 0.3.14 was used.
Glucose Turnover
A stable-label glucose tracer was infused in a time-variant
fashion to mimic the expected total appearance of glu-
cose [14]. At 06:00 hours, a primed (4mg/kg over 1min)
[6,6-2H2]glucose infusion (Cambridge Isotope Laboratories,
Andover, MA, USA) was started and continued at a fixed
rate of 0.04mg/kg/min until 08:00 hours. From 08:00 hours
until midnight the infusion of [6,6-2H2]glucose continued at
a variable rate to mimic the expected total systemic glucose
appearance (sum of endogenous glucose production and meal
attributable total glucose appearance; Ra_total) in post-meal
conditions and to reduce variations in the tracer-to-tracee ratio
[15].The infusion rate was varied at 15-min intervals, as shown
in Table S1. These infusion rates were derived from previous
studies on glucose absorption patterns of meals with different
glycaemic loads in young people with T1D [16].
Tracer-to-tracee ratios of [6,6-2H2]glucose were calculated
using ions mass/charge ratio (m/z)M+ 0 and M+ 2, based on
a method described previously [17]. The glucose turnover cal-
culations were based on the maximum likelihoodmethod [18],
modified for a Bayesian implementation in WinBUGS (MRC
Biostatistics Unit, Cambridge, UK) version 1.4.3. Ra_total rep-
resents total glucose appearance corresponding to the sum
of all meal-derived glucose (breakdown of sugars and com-
plex carbohydrates) and endogenous glucose production [16].
Ra_total and glucose disposal (Rd) were calculated for 24 h
from 08:00 hours on day 2 until 08:00 hours on day 3. Periph-
eral insulin sensitivity was calculated as the incremental area
under the Rd curve above fasting divided by the incremen-
tal plasma insulin concentration above fasting [19,20]. The
metabolic clearance of insulin was calculated as the incremen-
tal insulin delivery above fasting divided by the incremental
plasma insulin concentration above fasting.
Sampling and Assay
Blood samples were taken to measure plasma glucose and
insulin levels every 15 (postprandial period) to 60 (overnight)
min. Plasma glucose was measured using a YSI2300 STAT
Plus analyser (YSI, Farnborough, UK) and plasma insulin
by immunochemiluminometric assay (Invitron, Monmouth,
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Table 1. Study outcomes based on plasma glucose between 24:00 hours on day 1 until 08:00 hours on day 3 (32 h) is considered for analysis during
closed-loop therapy with standard prandial insulin boluses and closed-loop therapy with reduced prandial insulin boluses.
Closed-loop with
standard prandial
boluses (n= 8)
Closed-loop with
reduced prandial
boluses (n= 8) p
Primary outcome
Median (IQR) percentage of time spent in target of 3.9–10mmol/l 80 (65, 96) 74 (66, 84) 0.87
Secondary outcomes
Mean (s.d.) glucose, mmol/l 8.4 (0.9) 8.4 (0.9) 0.98
Median (IQR) standard deviation of glucose, mmol/l 1.9 (1.4, 2.3) 2.1 (1.8, 2.5) 0.40
Median (IQR) percentage of time spent in target of 3.9–8mmol/l 48 (30, 54) 42 (36, 52) 0.84
Hypoglycaemia: median (IQR), %
≤3.9mmol/l (%) 0.0 (0.0, 1.8) 0.0 (0.0, 1.5) 0.88
≤3.5mmol/l (%) 0.0 (0.0, 0.9) 0.0 (0.0, 0.9) 0.88
Median (IQR) low blood glucose index, unitless 0.2 (0.1, 0.5) 0.2 (0.1, 0.4) 0.93
Hyperglycaemia: median (IQR), %
>10mmol/l 18.0 (4.1, 34.2) 21.8 (16.3, 33.5) 0.87
>16.6mmol/l 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) —*
Median (IQR) insulin infusion, IU/h 1.5 (1.3, 1.6) 1.4 (1.2, 1.7) 0.20
Median (IQR) insulin concentration, pmol/l† 252 (198, 336) 186 (171, 260) 0.002
Median (IQR) insulin boluses, IU 25.7 (24.1, 29.4) 18.6 (17.6, 21.4) <0.001
Median (IQR) total insulin, IU 72.5 (63.6, 80.3) 61.9 (55.2, 75.0) 0.01
IQR, interquartile range; s.d., standard deviation.
*No subject had values >16.6mmol/l on either visit.
†One subject was excluded as a result of having a much greater insulin concentration on both visits.
UK). Venous blood samples for determination of background
glucose isotope enrichment were taken at 05:50, 05:55 and
06:00 hours. Samples for the determination of enriched
glucose and plasma glucose were taken at 07:45, 07:55
and 08:00 hours and then every 15–30min throughout the
study, except from midnight to 08:00 hours, when sam-
ples were taken hourly. Isotope ratios of [6,62H2]glucose
were measured by gas chromatography-mass spectrometry
on an Agilent GCMS 5975C MSD (Agilent Technologies,
Santa Clara, CA, USA) using selected ion monitoring of a
penta-O-trimethylsilyl-D-glucose-O-methyloxime derivative
to measure ions mass/charge ratio (m/z) 319.2 (M+ 0) and
321.2 (M+ 2) [17].
Statistical Analysis
The primary outcome was time spent with plasma glucose in
the target range (3.9–10mmol/l) between 24:00 hours on day 1
and 08:00 hours on day 3 (32 h). Secondary outcomes included
mean glucose, time spent with plasma glucose in the hypo-
glycaemia range (≤3.9 and ≤3.5mmol/l), low blood glucose
index, time spent with plasma glucose in the hyperglycemia
range (>10 and >16.6mmol/l), and insulin-related metrics
between 24:00 hours on day 1 and 08:00 hours on day 3 (32 h).
A repeated-measures regression model was fit to compare the
two treatments adjusting for period effect and based on the
ranked normal transformation (except formean glucose, which
was not transformed because it already had an approximate
normal distribution). Statistical analyses were performed using
sas 9.4. All p values are two-tailed and values <0.05 were con-
sidered to indicate statistical significance. Results are presented
as median (interquartile range) or mean (s.d.) unless stated
otherwise.
Results
Participants
A flowchart of participants through the study is shown in
Figure S1. We studied eight adolescents (three males) aged
15.9 (1.5) years, BMI 24 (3) kg/m2, HbA1c [8.9 (1.6)% or 74
(17)mmol/mol], diabetes duration 7 (2) years, on insulin pump
therapy for 4 (2) years, and total daily insulin dose 59 (40,
83) IU/day [0.9 (0.7, 1.1) IU/kg/day].
Closed-loop Glucose Control
The time spent with plasma glucose levels within the target
range of 3.9–10mmol/l (the primary outcome) was similar
between the two interventions (Table 1 and Figure 1). This
outcome was similar when evaluated based on sensor glucose
(Table S3). Hypoglycaemia occurred once 1.5 h after a meal
during closed-loop with standard prandial boluses. Total
insulin delivery and plasma insulin were lower with reduced
prandial insulin boluses. Insulin infusion rates were similar
between the two interventions in the two overnight periods.
Plasma insulin levels, however, were lower overnight with
reduced plasma insulin boluses [first night: 137 (106, 192) vs
172 (126, 256) pmol/l; p= 0.01; second night: 161 (148, 234) vs
196 (159, 252) pmol/l; p= 0.09; pooled nights: 160 (136, 192)
vs 191 (133, 252) pmol/l; p= 0.01], as shown in Figure 3. Study
outcomes during day-time and night-time are also shown in
Table S4.
Glucose Turnover
Both Ra_total and Rd were similar on the two occasions
(Figure 2). Insulin sensitivity and plasma insulin clearance
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(A)
(B)
(C)
Figure 1. Plasma glucose concentration (A), basal insulin infusion rates (B) and the plasma insulin levels (C) during closed-loop therapy with standard
prandial insulin boluses (grey line) and closed-loop therapy with reduced prandial boluses (black line). Values are median, interquartile ranges.
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(A)
(B)
Figure 2. (A) Total glucose appearance and (B) disposal (mean, standard
error) from 08:00 hours on day 2 for 24 h during closed-loop therapy
with standard prandial boluses (grey line) and closed-loop with reduced
prandial boluses (black line).
were also similar (Table 2). Similarly, no difference in glucose
turnover between treatments was found when the overnight
period was considered (Table S2).
Continuous Glucose Monitoring
The accuracy of sensor glucose measurements was calculated
as compared with plasma glucose data measured by YSI2300
STAT Plus analyser. Each YSI glucose measurement was paired
with an interpolated sensor value only if this existed within
±6min of the YSI glucose measurement.This approach is simi-
lar to that used to calculate sensor accuracy in previous clinical
studies. The median absolute relative difference of Navigator
CGM was 7.5% and the mean absolute relative difference was
9.7%.
Discussion
In the present study we showed that closed-loop insulin
delivery coupled with a 25% reduction in prandial insulin
achieves similar glucose control compared with closed-loop
with standard boluses in a group of adolescents with T1D.
The time spent with plasma glucose levels within the target
range of 3.9–10mmol/l was 74% when prandial boluses were
reduced and 80% with standard boluses (p= 0.87). Mean
plasma glucose levels were identical [8.4 (0.9)mmol/l, reduced
vs standard bolus; p= 0.98].
Closed-loop insulin delivery is particularly efficacious
when coupled with manual prandial insulin boluses to offset
delays associated with absorption of subcutaneous insulin
and glucose sensing. Weinzimer et al. [21] observed that
postprandial glucose control improved when priming insulin
bolus was given with meals during closed-loop using a
proportional-integral-derivate algorithm. El-Khatib et al. [22]
demonstrated improved postprandial control with adaptive
meal priming boluses compared with a scheme avoiding meal
boluses during a bi-hormonal closed-loop in adolescents and
adults. Haidar et al. [23] showed that carbohydrate-matching
insulin bolus improved post-breakfast glycaemic control as
compared with weight-dependent bolus during bi-hormonal
closed-loop in adults.
The calculation of prandial insulin based on the amount
of carbohydrates (carbohydrate counting) is commonly pro-
moted by educational interventions [24]. Insulin pumps are
equipped with in-built bolus calculators employing premeal
glucose levels and insulin on board. Combining carbohydrate
counting with closed-loop insulin delivery builds on existing
self-management practice and we have observed its efficacy in
adolescents over a 36-h period at a clinical research facility [13];
however, episodes of hypoglycaemia that occurred after meals
were most likely related to overestimation of prandial insulin
doses and occurred even though basal insulin delivery was
stopped by the control algorithm in the postprandial period.
The present study used the same protocol that we used
previously in adolescents with suboptimum glycaemic control
Table 2. Glucose turnover from 08:00 hours on day 2 until midnight on day 2.
Closed-loop with
standard prandial boluses (n= 8)
Closed-loop with reduced
prandial boluses (n= 8) p
Insulin concentration, pmol/l* 317 (252, 435) 224 (204, 346) 0.009
Ra_total, μmol/kg/min 25.4 (21.0, 29.2) 26.3 (21.9, 28.0) 0.19
Rd, μmol/kg/min 25.2 (21.2, 28.8) 25.8 (21.0, 26.9) 0.46
Insulin metabolic clearance of insulin, ml/kg* 15.7 (8.3, 17.5) 16.6 (9.2, 20.9) 0.16
Insulin sensitivity, nmol/kg/min/pmol/l* 58.1 (36.3, 74.0) 81.2 (52.2, 94.0) 0.22
Values are median (interquartile range). Ra_total, total glucose appearance; Rd, glucose disposal.
*One subject was excluded as a result of having a much greater insulin concentration on both visits.
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Figure 3. Mean plasma insulin levels on the first and second night during
closed-loop therapy with standard prandial insulin boluses (light grey
boxes) and closed-loop with reduced prandial boluses (dark grey boxes).
[13]. Only one episode of hypoglycaemia occurred 1.5 h after
a meal when a standard bolus was given and none occurred
when reduced boluses were administered, with no direct evi-
dence that reduced bolusing may reduce the risk of hypogly-
caemia. Closed-loop insulin infusion did not differ during the
two study periods; the closed-loop algorithm did not increase
basal insulin delivery when reduced boluses were given for
meals to compensate for reduced meal insulin doses. As a con-
sequence, both total insulin delivery and plasma insulin con-
centration were significantly lower when reduced boluses were
administered; however, whereas reduced insulin levels during
the day with reduced boluses were to be expected, the change
in overnight insulin was unexpected. Reduced plasma insulin
levels were documented overnight, as shown in Figures 2 and 3
and Table S2. Glucose turnover was unchanged between the
two treatment approaches (Table 2) even during the overnight
period (Table S2).The rate of Rd was comparable, but was asso-
ciated with lower plasma insulin levels with reduced boluses
suggesting saturation of insulin action as higher insulin levels
did not lead to an increase in Rd. Alternatively, excess prandial
insulin might increase counter-regulatory responses. A reduc-
tion in insulin exposure may be particularly beneficial during
adolescence, at an age when increased insulin resistance and
consequently higher insulin needsmay lead to weight gain [25].
For this reason, closed-loop therapy with reduced meal boluses
may be a more favourable alternative for adolescents.
The strength of the present study is its use of tracer dilution
methodology to assess the metabolic consequences of reduced
prandial boluses, the relatively long duration of the study, and
the use of a well-studied controller.The weaknesses include the
relatively small number of subjects but we targeted those most
likely to benefit from closed-loop therapy with suboptimally
controlled glucose levels.
In conclusion, closed-loop insulin delivery with 25% reduc-
tion of prandial boluses achieved similar glucose control
and glucose turnover and may be preferable in adolescents
with inadequate glucose control. Further investigations are
warranted to investigate the reasons for the similar glucose
control at lower insulin levels.
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